TABLE OF CONTENTS
Volume 86, Issue 2 (August 2009)
Editorial |
News & Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Erratum & Corrigendum
In This Issue
In This Issue
In This Issue
Clin Pharmacol Ther 86: 115; doi:10.1038/clpt.2009.130
See also: Macroscopy by KeiserSee also: Commentary by Bruno & ClaretSee also: Article by Wang et al. See also: State of the Art by Gross & WeitzSee also: Article by Hansen et al. See also: Article by VanhoutteEditorial
Editorial
Vascular Medicine: A Look Forward
S A Holstein and R J Hohl
Clin Pharmacol Ther 86: 117-119; doi:10.1038/clpt.2009.125
News & Views
Highlights
Highlights
Clin Pharmacol Ther 86: 120-121; doi:10.1038/clpt.2009.131
ASCPT News
ASCPT News
Clin Pharmacol Ther 86: 122-123; doi:10.1038/clpt.2009.110
Macroscopy
Vascular Pharmacology: Opportunities for Intervention
J Keiser
Clin Pharmacol Ther 86: 124-126; doi:10.1038/clpt.2009.111
Perspectives
Point/Counterpoint
Are Drug-Eluting Stents Safe?: Definitely! Or Probably...Possibly? Or Maybe Not Yet...
G Nakazawa, E Ladich and R Virmani
Clin Pharmacol Ther 86: 127-130; doi:10.1038/clpt.2009.113
See also: Point/Counterpoint by Garg & SerruysDrug-Eluting Stents Are Safe
S Garg and P Serruys
Clin Pharmacol Ther 86: 130-132; doi:10.1038/clpt.2009.99
See also: Point/Counterpoint by Nakazawa et al.Commentaries
A Holy Grail of Clinical Pharmacology: Prediction of Drug Pharmacokinetics and Pharmacodynamics in the Individual Patient
L Z Benet
Clin Pharmacol Ther 86: 133-134; doi:10.1038/clpt.2009.102
See also: Article by Tomalik-Scharte et al.A Truncated Erythropoietin Receptor EPOR-T Is Associated With Hypertension Susceptibility
S G Carruthers
Clin Pharmacol Ther 86: 134-136; doi:10.1038/clpt.2009.119
See also: Article by Ioka et al.On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies
R Bruno and L Claret
Clin Pharmacol Ther 86: 136-138; doi:10.1038/clpt.2009.97
See also: Article by Wang et al.State of the Art
State of the Art
New Antithrombotic Drugs
P L Gross and J I Weitz
Clin Pharmacol Ther 86: 139-146; advance online publication, June 24, 2009; doi:10.1038/clpt.2009.98
Research
Articles
Plasma 4
-Hydroxycholesterol: An Endogenous CYP3A Metric?
D Tomalik-Scharte, D Lütjohann, O Doroshyenko, D Frank, A Jetter and U Fuhr
Clin Pharmacol Ther 86: 147-153; advance online publication, May 20, 2009; doi:10.1038/clpt.2009.72
See also: Commentary by BenetHypertension Induced by Erythropoietin Has a Correlation With Truncated Erythropoietin Receptor mRNA in Endothelial Progenitor Cells of Hemodialysis Patients
T Ioka, S Tsuruoka, C Ito, H Iwaguro, T Asahara, A Fujimura and E Kusano
Clin Pharmacol Ther 86: 154-159; advance online publication, May 20, 2009; doi:10.1038/clpt.2009.74
See also: Commentary by CarruthersCannabis Coadministration Potentiates the Effects of "Ecstasy" on Heart Rate and Temperature in Humans
G J Dumont, C Kramers, F C Sweep, D J Touw, J G van Hasselt, M de Kam, J M van Gerven, J K Buitelaar and R J Verkes
Clin Pharmacol Ther 86: 160-166; advance online publication, May 13, 2009; doi:10.1038/clpt.2009.62
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y Wang, C Sung, C Dartois, R Ramchandani, B P Booth, E Rock and J Gobburu
Clin Pharmacol Ther 86: 167-174; advance online publication, May 13, 2009; doi:10.1038/clpt.2009.64
Abstract | Full Text | PDF | Supplementary information
See also: Commentary by Bruno & ClaretEffect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies
S A Stoch, S Zajic, J Stone, D L Miller, K Van Dyck, M J Gutierrez, M De Decker, L Liu, Q Liu, B B Scott, D Panebianco, B Jin, L T Duong, K Gottesdiener and J A Wagner
Clin Pharmacol Ther 86: 175-182; advance online publication, May 6, 2009; doi:10.1038/clpt.2009.60
Generating Genome-Scale Candidate Gene Lists for Pharmacogenomics
N T Hansen, S Brunak and R B Altman
Clin Pharmacol Ther 86: 183-189; advance online publication, April 15, 2009; doi:10.1038/clpt.2009.42
A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients With Relapsed or Refractory Non-Hodgkin's or Hodgkin's Lymphoma
D R Mould, K Sweeney, S B Duffull, E Neylon, P Hamlin, S Horwitz, F Sirotnak, M Fleisher, M E Saunders and O A O'Connor
Clin Pharmacol Ther 86: 190-196; advance online publication, May 27, 2009; doi:10.1038/clpt.2009.80
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J E Keskitalo, O Zolk, M F Fromm, K J Kurkinen, P J Neuvonen and M Niemi
Clin Pharmacol Ther 86: 197-203; advance online publication, May 27, 2009; doi:10.1038/clpt.2009.79
The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz
T W Mahungu, D Nair, C J Smith, D Egan, M Youle, M A Johnson, S H Khoo, D J Back and A Owen
Clin Pharmacol Ther 86: 204-211; advance online publication, May 27, 2009; doi:10.1038/clpt.2009.78
Discovery & Development
Translational Medicine
COX-1 and Vascular Disease
P M Vanhoutte
Clin Pharmacol Ther 86: 212-215; advance online publication, June 24, 2009; doi:10.1038/clpt.2009.108
Pharmacological Treatment for Heart Failure: A View From the Brain
R B Felder, Y Yu, Z-H Zhang and S-G Wei
Clin Pharmacol Ther 86: 216-220; advance online publication, June 24, 2009; doi:10.1038/clpt.2009.117
Erratum & Corrigendum
CORRIGENDUM: Abstract PI-57: Pharmacokinetic/Pharmacodynamic Modeling of Inhibition of Serotonin and Norepinephrine Uptake by Duloxetine and Escitalopram in Healthy Subjects
Clin Pharmacol Ther 86: 221; doi:10.1038/clpt.2009.81
